-
Your selected country is
Japan
- Change country/language
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD Rhapsody™ TCR/BCR Profiling Assays (VDJ Assays) | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD Rhapsody™ TCR/BCR Profiling Assays (VDJ Assays) | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- Japan (Japanese)
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Pharmingen™ Z-FA-FMK, Negative Control for Caspase Inhibitors
(RUO)Flow cytometric analysis of apoptosis in Jurkat cells (Human T-cell leukemia; ATCC TIB-152). Jurkat cells were preincubated with the following: no inhibitor (upper left and bottom left panels), 20 µM Z-LEHD-FMK (a caspase-9 inhibitor) (upper center and bottom center panels) or 20 µM Z-FA-FMK negative control inhibitor (upper right and bottom right panels) for 30 minutes, and then either left untreated (bottom row) or treated with 4 µM campthothecin for 3 hours (top row). Following incubation, cells were collected and stained with PE Annexin V (Cat. No. 559763) to identify cells undergoing apoptosis. The results indicate that in campthothecin treated cells, approximately 42% of the cells were induced to undergo apoptosis and the use of the negative control inhibitor, Z-FA-FMK, showed similar results to the treated cells without inhibitor (right panels), indicating that the negative control inhibitor did not attenuate apoptosis.
BD Pharmingen™ Z-FA-FMK, Negative Control for Caspase Inhibitors
Regulatory Statusの凡例
Becton, Dickinson and Companyの書面による明示的な許諾を得た使用以外での製品の使用は固く禁じられています。
説明
Members of the caspase family play key roles in inflammation and mammalian apoptosis. Z-FA-FMK is a negative control inhibitor which has no inhibitory effect on apoptosis mediated by caspases and can only inhibit cysteine proteases (those not requiring P1 Asp inhibitors) such as Cathepsin B. Z-FA-FMK has a molecular weight of 386 Daltons.
調製と保管タイトルテキスト
Store lyophilized Z-FA-FMK at -20˚C. Reconstitute Z-FA-FMK in DMSO before use. Reconstituted Z-FA-FMK may be stored in small aliquots at -20˚C.
推奨アッセイ手順
Z-FA-FMK is designed to be used in both in vivo and in vitro cell based assays as a negative control in assays used to measure apoptosis. Reconstitute 1.0 mg of Z-FA-FMK in DMSO. A 10 mM stock solution may be made by dissolving 1.0 mg of Z-FA-FMK in 263 µl DMSO. The final concentration of Z-FA-FMK needed may vary between experimental systems and investigators are encouraged to titrate. As a precautionary note, please do not exceed a final DMSO concentration of 0.2% as higher levels may cause cellular toxicity and mask the effects of the caspase inhibitor.
製品通知
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
コンパニオン製品
Development References (2)
-
Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol. 1999; 178(2):133-143. (Biology). View Reference
-
Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998; 281(5381):1312-1316. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Report a Site Issue
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.